Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

0 result

  • Topics : Diseases and conditions
  • Active substance : pyrazinamide
Filter
Topic
  • Diseases and conditions (2)
  • Plus ...
    • Respiratory tract diseases (2)
    • Plus ...
      • Pulmonary and pleural diseases (2)
    • Infectious diseases (2)
    • Plus ...
      • Bacterial infections (2)
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Diagnostic techniques and procedures (1)
    • Plus ...
      • Biology (laboratory tests) (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Health technology assessment (1)
  • Practice Guidelines and Other Guides (1)
  • Plus ...
    • Chronic disease guide (1)
Language
  • Français (2)
Active substance
  • isoniazide (2)
  • pyrazinamide (2)
  • rifampicine (2)
 More filter Other Filter Icon
Search Export

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
KzB1XuMftt2xLrsd